Table of Contents
Dataset Papers in Medicine
Volume 2013 (2013), Article ID 580927, 5 pages
http://dx.doi.org/10.1155/2013/580927
Dataset Paper

Efficacy and Safety of Botulinum Toxin A for Treating Bladder Hyperactivity in Children and Adolescents with Neuropathic Bladder Secondary to Myelomeningocele

Division of Pediatric Surgery, Second University of Naples, Via S. Pansini 5, 80131 Naples, Italy

Received 4 October 2012; Accepted 6 November 2012

Academic Editors: P. Crispen, T. Efferth, P. Ferrante, and B. Weinstock-Guttman

Copyright © 2013 Antonio Marte et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Madersbacher, “Neurogenic bladder dysfunction in patients with myelomeningocele,” Current Opinion in Urology, vol. 12, no. 6, pp. 469–472, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Schulte-Baukloh, T. Michael, B. Stürzebecher, and H. H. Knispel, “Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder,” European Urology, vol. 44, no. 1, pp. 139–143, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. G. Del Popolo, La Tossina Botulinica in Neurourologia, Somipar, 2001.
  4. A. Reitz, M. Stöhrer, G. Kramer et al., “European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity,” European Urology, vol. 45, no. 4, pp. 510–515, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Sussman, V. Patel, G. Del Popolo, W. Lam, D. Globe, and P. Pommerville, “Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenicdetrusor overactivity,” Neurourology and Urodynamics. View at Publisher · View at Google Scholar
  6. K. F. Neel, M. Salem, and S. Soliman, “Total endoscopic management (TEM approach) of children with non-compliant neuropathic bladder: a preliminary report,” Journal of Pediatric Urology, vol. 4, no. 2, pp. 124–126, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. E. J. McGuire, J. R. Woodside, T. A. Borden, and R. M. Weiss, “Prognostic value of urodynamic testing in myelodysplastic patients,” Journal of Urology, vol. 126, no. 2, pp. 205–209, 1981. View at Google Scholar · View at Scopus
  8. A. M. Houle, R. F. Gilmour, B. M. Churchill, M. Gaumond, and B. Bissonnette, “What volume can a child normally store in the bladder at a safe pressure?” Journal of Urology, vol. 149, no. 3, pp. 561–564, 1993. View at Google Scholar · View at Scopus
  9. A. Marte, M. Borrelli, M. D. Sabatino et al., “Effectiveness of botulinum-A toxin for the treatment of refractory overactive bladder in children,” European Journal of Pediatric Surgery, vol. 20, no. 3, pp. 153–157, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Blasi, E. R. Chapman, E. Link et al., “Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25,” Nature, vol. 365, no. 6442, pp. 160–163, 1993. View at Publisher · View at Google Scholar · View at Scopus
  11. O. Dolly, “Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins,” Headache, vol. 43, no. 1, pp. S16–S24, 2003. View at Google Scholar · View at Scopus
  12. P. Denys, A. Even-Schneider, I. T. Escudie, D. B. Smail, N. Ayoub, and E. Chartier-Kastler, “Efficacy of botulinum toxin A for the treatment of detrusor hyperreflexia,” Annales de Readaptation et de Medecine Physique, vol. 46, no. 6, pp. 326–328, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Leippold, A. Reitz, and B. Schurch, “Botulinum toxin as a new therapy option for voiding disorders: current state of the art,” European Urology, vol. 44, no. 2, pp. 165–174, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Schurch, M. Stöhrer, G. Kramer, D. M. Schmid, G. Gaul, and D. Hauri, “Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results,” Journal of Urology, vol. 164, no. 3, pp. 692–697, 2000. View at Google Scholar · View at Scopus
  15. U. Mehnert, S. Boy, M. Schmid et al., “A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging,” World Journal of Urology, vol. 27, no. 3, pp. 397–403, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. H. Schulte-Baukloh, J. Herholz, H. Bigalke, K. Miller, and H. H. Knispel, “Results of a BoNT/An antibody study in children and adolescents after onabotulinumtoxin A (Botox) detrusor injection,” Urologia Internationalis, vol. 87, no. 4, pp. 434–438, 2011. View at Google Scholar
  17. X. Gamé, P. Mouracade, E. Chartier-Kastler et al., “Botulinum toxin-A (Botox) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review,” Journal of Pediatric Urology, vol. 5, no. 3, pp. 156–164, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Grosse, G. Kramer, and M. Stöhrer, “Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence,” European Urology, vol. 47, no. 5, pp. 653–659, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Wefer, B. Ehlken, J. Bremer et al., “Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany,” World Journal of Urology, vol. 28, no. 3, pp. 385–390, 2010. View at Publisher · View at Google Scholar · View at Scopus